{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:03:23Z","timestamp":1789506203973,"version":"build-2803163510"},"reference-count":39,"publisher":"American Chemical Society (ACS)","issue":"15","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong Province","doi-asserted-by":"publisher","award":["2022CXPT038"],"award-info":[{"award-number":["2022CXPT038"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017445","name":"Science Fund for Distinguished Young Scholars of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021YQ53"],"award-info":[{"award-number":["ZR2021YQ53"]}],"id":[{"id":"10.13039\/100017445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004195","name":"Ocean University of China","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100004195","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","award":["tsqn201909171"],"award-info":[{"award-number":["tsqn201909171"]}],"id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010954","name":"Qingdao National Laboratory for Marine Science and Technology","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100010954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2804400"],"award-info":[{"award-number":["2022YFC2804400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Qingdao Key Technology Research and Industrialization Demonstration Projects","doi-asserted-by":"publisher","award":["24-1-4-xxgg-15-nsh"],"award-info":[{"award-number":["24-1-4-xxgg-15-nsh"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer is a common male malignancy. Although androgen deprivation therapy (ADT) is initially effective, it often leads to castration-resistant prostate cancer (CRPC) eventually. Second-generation androgen antagonists are the standard therapy for CRPC. However, resistance develops due to mutations or splice variants in the ligand binding domain (LBD) of the androgen receptor (AR). Therefore, the development of novel, efficient, and safe therapeutic agents for CRPC is of great significance. In this study, we designed and synthesized compound LYA914 as a proteolysis-targeting chimera (PROTAC) degrader targeting the conserved DNA binding domain (DBD) of AR, which can simultaneously degrade AR and its variant AR-V7. It demonstrated effective antiproliferative effects in enzalutamide-insensitive\/resistant cells. In a VCaP castrated tumor cell model, oral administration of LYA914 obviously inhibited tumor growth, demonstrating superior efficacy compared to enzalutamide. These findings underscore the promising potential of LYA914 for the treatment of CRPC.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c01463","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T02:11:41Z","timestamp":1753755101000},"page":"16593-16612","source":"Crossref","is-referenced-by-count":4,"title":["Discovery of\nLYA914, An Orally Bioavailable PROTAC\nDegrader Targeting the DNA Binding Domain of the Androgen Receptor\nfor the Treatment of CRPC"],"prefix":"10.1021","volume":"68","author":[{"given":"Yan","family":"Lv","sequence":"first","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoxin","family":"Dai","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Chen","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ge","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjun","family":"Ma","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Ma","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8108-1698","authenticated-orcid":true,"given":"Chong","family":"Qin","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Pilot National Laboratory for Marine Science and Technology , , , ,","place":["Qingdao, Shandong, China, 266237"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"3","key":"2026073103083630000_cit1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics\n2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for\n36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca-Cancer J. Clin."},{"issue":"1","key":"2026073103083630000_cit2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer Statistics,\n2023","volume":"73","author":"Siegel","year":"2023","journal-title":"Ca-Cancer J. Clin."},{"issue":"1","key":"2026073103083630000_cit3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer Statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA A Cancer J Clinicians"},{"issue":"10","key":"2026073103083630000_cit4","doi-asserted-by":"publisher","first-page":"10139","DOI":"10.1021\/acs.jmedchem.5c00226","article-title":"PSMA-Guided PROTAC\nDegraders for Tumor-Specific Protein Degradation in Prostate Cancer","volume":"68","author":"Meng","year":"2025","journal-title":"J. Med. Chem."},{"issue":"9","key":"2026073103083630000_cit5","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1021\/cr020456u","article-title":"Chemistry\nand Structural Biology\nof Androgen Receptor","volume":"105","author":"Gao","year":"2005","journal-title":"Chem. Rev."},{"issue":"4","key":"2026073103083630000_cit6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2174\/1389450111314040005","article-title":"Androgen Receptor\nGene Rearrangements: New Perspectives\non Prostate Cancer Progression","volume":"14","author":"Brand","year":"2013","journal-title":"Curr. Drug Targets"},{"issue":"19","key":"2026073103083630000_cit7","doi-asserted-by":"publisher","first-page":"17290","DOI":"10.1021\/acs.jmedchem.4c01100","article-title":"Discovery of a Highly\nPotent PROTAC Degrader of P300\/CBP Proteins for the Treatment of Enzalutamide-Resistant\nProstate Cancer","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026073103083630000_cit8","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1021\/acs.jmedchem.2c01970","article-title":"Design Synthesis, and Biological Evaluation of Androgen Receptor\n(AR) Antagonist-Heat Shock Protein 90 (Hsp90) Inhibitor Conjugates\nfor Targeted Therapy of Castration-Resistant Prostate Cancer","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"6","key":"2026073103083630000_cit9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2174\/156800907781662248","article-title":"Cross-Talk Between the Androgen Receptor\nand the Phosphatidylinositol 3-Kinase\/Akt Pathway in Prostate Cancer","volume":"7","author":"Wang","year":"2007","journal-title":"Curr. Cancer Drug Targets"},{"issue":"10","key":"2026073103083630000_cit10","doi-asserted-by":"publisher","first-page":"10268","DOI":"10.1021\/acs.jmedchem.5c00443","article-title":"Rational Design of\nDual Degraders by Incorporating Molecular Glue\nStructural Features into PROTAC Degraders","volume":"68","author":"Zhang","year":"2025","journal-title":"J.\nMed. Chem."},{"issue":"12","key":"2026073103083630000_cit11","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41589-022-01151-y","article-title":"Targeting Androgen Receptor Phase\nSeparation to Overcome\nAntiandrogen Resistance","volume":"18","author":"Xie","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"2026073103083630000_cit12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen Deprivation\nTherapy: Progress in Understanding Mechanisms of Resistance and Optimizing\nAndrogen Depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat. Rev. Urol."},{"issue":"1","key":"2026073103083630000_cit13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.eururo.2017.08.012","article-title":"Moving Towards Precision\nUrologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer\nand Mutated Forms of the Androgen Receptor Using the Novel Inhibitor\nDarolutamide (ODM-201)","volume":"73","author":"Borgmann","year":"2018","journal-title":"European Urology"},{"issue":"8","key":"2026073103083630000_cit14","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1200\/JCO.1996.14.8.2250","article-title":"Double-Blind Randomized\nStudy of Primary Hormonal Treatment of Stage D2 Prostate Carcinoma:\nFlutamide versus Diethylstilbestrol","volume":"14","author":"Chang","year":"1996","journal-title":"J. Clin.\nOncol."},{"issue":"5","key":"2026073103083630000_cit15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1159\/000019634","article-title":"A Randomised\nComparison of \u2018Casodex\u2019TM (Bicalutamide) 150 Mg Monotherapy\nversus Castration in the Treatment of Metastatic and Locally Advanced\nProstate Cancer","volume":"33","author":"Tyrrell","year":"1998","journal-title":"Eur. Urol."},{"issue":"21","key":"2026073103083630000_cit16","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and\nIncreased Survival in Metastatic Prostate Cancer","volume":"364","author":"De Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"2026073103083630000_cit17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide\nin Metastatic Prostate Cancer before Chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"2026073103083630000_cit18","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1002\/jcb.25928","article-title":"Molecular\nDynamics Studies on the Enzalutamide Resistance Mechanisms Induced\nby Androgen Receptor Mutations","volume":"118","author":"Liu","year":"2017","journal-title":"J. Cell. Biochem."},{"issue":"9","key":"2026073103083630000_cit19","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3390\/ijms18091823","article-title":"A Molecular Modeling\nStudy of the Hydroxyflutamide Resistance Mechanism Induced by Androgen\nReceptor Mutations","volume":"18","author":"Liu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"45","key":"2026073103083630000_cit20","doi-asserted-by":"publisher","first-page":"6935","DOI":"10.1038\/s41388-020-01479-6","article-title":"Role of Androgen Receptor Splice\nVariant-7 (AR-V7) in Prostate Cancer Resistance to 2nd-Generation\nAndrogen Receptor Signaling Inhibitors","volume":"39","author":"Zhu","year":"2020","journal-title":"Oncogene"},{"issue":"1","key":"2026073103083630000_cit21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen Receptor\nSplice Variant-7 Expression Emerges with Castration Resistance in\nProstate Cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"13","key":"2026073103083630000_cit22","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective Multicenter\nValidation of Androgen Receptor Splice Variant 7 and Hormone Therapy\nResistance in High-Risk Castration-Resistant Prostate Cancer: The\nPROPHECY Study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"2026073103083630000_cit23","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/med.21961","article-title":"Current and Emerging Approaches to\nNoncompetitive AR Inhibition","volume":"43","author":"Riley","year":"2023","journal-title":"Med. Res. Rev."},{"issue":"15","key":"2026073103083630000_cit24","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1021\/jm500802j","article-title":"Discovery\nof Small-Molecule Inhibitors Selectively Targeting the DNA-Binding\nDomain of the Human Androgen Receptor","volume":"57","author":"Li","year":"2014","journal-title":"J. Med.\nChem."},{"issue":"3","key":"2026073103083630000_cit25","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1158\/1535-7163.MCT-20-0417","article-title":"Effects\nof MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and\nAndrogen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy","volume":"20","author":"Lee","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"2026073103083630000_cit26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ccr.2010.04.027","article-title":"Regression of Castrate-Recurrent\nProstate Cancer by\na Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen\nReceptor","volume":"17","author":"Andersen","year":"2010","journal-title":"Cancer Cell"},{"issue":"7","key":"2026073103083630000_cit27","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1172\/JCI66398","article-title":"An Androgen Receptor\nN-Terminal Domain Antagonist for\nTreating Prostate Cancer","volume":"123","author":"Myung","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"16","key":"2026073103083630000_cit28","doi-asserted-by":"publisher","first-page":"11158","DOI":"10.1021\/acs.jmedchem.3c00585","article-title":"Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC\nDegrader of the Androgen Receptor Targeting N-Terminal Domain for\nthe Treatment of Prostate Cancer","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"6241","key":"2026073103083630000_cit29","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide Conjugation as a Strategy\nfor in Vivo Target Protein Degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"issue":"3","key":"2026073103083630000_cit30","doi-asserted-by":"publisher","first-page":"103985","DOI":"10.1016\/j.isci.2022.103985","article-title":"Profiling of Diverse Tumor Types\nEstablishes the Broad Utility of VHL-Based ProTaCs and Triages Candidate\nUbiquitin Ligases","volume":"25","author":"Luo","year":"2022","journal-title":"iScience"},{"issue":"5","key":"2026073103083630000_cit31","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.70009","article-title":"CRBN-PROTACs in Cancer\nTherapy: From\nMechanistic Insights to Clinical Applications","volume":"104","author":"Thapa","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"key":"2026073103083630000_cit32","doi-asserted-by":"publisher","first-page":"116041","DOI":"10.1016\/j.ejmech.2023.116041","article-title":"Journey of Von Hippel-Lindau (VHL)\nE3 Ligase in PROTACs Design: From VHL Ligands to VHL-Based Degraders","volume":"265","author":"Setia","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"2026073103083630000_cit33","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1021\/acs.jmedchem.1c01774","article-title":"Discovery of the First-in-Class Agonist-Based\nSOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS\nMutations","volume":"65","author":"Zhou","year":"2022","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026073103083630000_cit34","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41585-023-00726-1","article-title":"Preclinical\nModels of Prostate Cancer\n\u2500 Modelling Androgen Dependency and Castration Resistance in\nVitro, Ex Vivo and in Vivo","volume":"20","author":"Germain","year":"2023","journal-title":"Nat. Rev. Urol."},{"issue":"9","key":"2026073103083630000_cit35","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876L Mutation\nin Androgen Receptor Confers Genetic and Phenotypic Resistance to\nMDV3100 (Enzalutamide)","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discovery"},{"issue":"22","key":"2026073103083630000_cit36","doi-asserted-by":"publisher","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-19-1458","article-title":"Orally Bioavailable Androgen Receptor Degrader, Potential\nNext-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer","volume":"25","author":"Ponnusamy","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2026073103083630000_cit37","doi-asserted-by":"publisher","first-page":"115793","DOI":"10.1016\/j.ejmech.2023.115793","article-title":"Current Advances and Development\nStrategies of Orally Bioavailable PROTACs","volume":"261","author":"Zeng","year":"2023","journal-title":"Eur.\nJ. Med. Chem."},{"issue":"7","key":"2026073103083630000_cit38","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1124\/dmd.122.001154","article-title":"Industry Perspective on the Pharmacokinetic\nand Absorption, Distribution, Metabolism, and Excretion Characterization\nof Heterobifunctional Protein Degraders","volume":"51","author":"Volak","year":"2023","journal-title":"Drug\nMetab. Dispos"},{"issue":"4","key":"2026073103083630000_cit39","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1021\/acs.jmedchem.3c01598","article-title":"A Potent SOS1\nPROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C\nInhibitor","volume":"67","author":"Lv","year":"2024","journal-title":"J. Med. Chem."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c01463","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/15\/16593\/66298976\/acs.jmedchem.5c01463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/15\/16593\/66298976\/acs.jmedchem.5c01463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:08:46Z","timestamp":1785481726000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/15\/16593\/5235001\/Discovery-of-LYA914-An-Orally-Bioavailable-PROTAC"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":39,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,7,28]]},"published-print":{"date-parts":[[2025,8,14]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01463","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}